Good afternoon, everyone. Welcome to the Emergent presentation. Emergent is a very unique healthcare company, a unique business model. We partner with governments around the world on biodefense, which is an important area, especially in this increasingly dangerous world we live in. We make products for some of the most difficult product areas that have significant barriers to entry. For example, we make a vaccine for smallpox. Once again, one of the number one viral biodefense or bioterrorist threats. We also make a product for anthrax, the number one bacterial problem or bioterrorist threat. We also make a product for the most lethal toxin out there, botulism, which is also considered to be one of the most important bioterrorist threats. Of course, today in the news, you also see about Ebola. We have a product that's in development and scale-up for Ebola as well, in terms of a therapeutic treatment. As you can see, these products are very difficult to make. They're very dangerous products, and we have significant barriers to entry. For example, when you're trying to create a live attenuated virus vaccine, you need to obviously make products that are going to be safe for all the employees that deal with them, but also obviously, very helpful for the patients that potentially use the product. It's important to think about a company like Emergent relative to this longevity of our product portfolio. Let me talk about specifically. Try and advance the slide, sir. I'm going to be making some forward-looking comments, and you'll see my safe harbor statements there to refer you to our SEC filings. If I can go to the next slide. Next slide, please. You can see our team, our experienced and trusted management team, has decades of experience in healthcare and specifically experience in this area of biodefense. The other area in which we can play in beyond that is we're the number one player in opioid overdose treatments with our NARCAN product. We lead the world when it comes to the biodefense area with the number one portfolio of products, and we also lead in the area of opioid overdose with the number one brand for opioid overdose treatment, NARCAN. Those are our two areas that we play in, important areas to be clear, in terms of looking at public health threats around the world, and our team is very much focused on continuing to protect and save lives as our mission. If I go to my next slide, you'll see the portfolio. The portfolio is the most diverse biodefense medical countermeasure portfolio and also has the naloxone product, specifically NARCAN, and also KLOXXADO. We are, as I said, the leader. We've been doing the biodefense world for 25+ years, and we have a very durable business model. We make the product initially for governments around the world, especially the United States. Beyond making it for them initially, we also do much of the testing of the potency, the stability of these products. There's an ongoing preparation that we provide, not only making the product, but then also servicing the product, which is important for governments as they stockpile products. They need to know that that product in their stockpile is potent and has a durable supply chain just in case any actual crisis develops. We make those products. We are prepared. We help the governments prepare for these types of products and issues around the world. Hopefully, we'll never need them, but it's like a fire extinguisher. Making sure you have the product on hand just in case something goes wrong. If I go to my next slide, it's the manufacturing partnerships that we make products. I joined the company in 2024. We've streamlined this network of manufacturing sites, to be clear. We've got two primary hub sites. One of it is in Lansing, Michigan. It's making our BioThrax and CYFENDUS product. And another one in Winnipeg, Canada, that makes many of our plasma purification products like BAT, Anthrasil, and also the other products we make there. We also make our ACAM2000 active substance, and we make a fill finish facility in Rockville, Maryland, that is also available. We've got access to a large drug substance facility, all as part of our streamlined amount of manufacturing network. Capabilities we have, we have capabilities in drug substance or API. We have capabilities in fill finish. We also have the capability to work with live attenuated virus and even can do lyophilization of that product if need be. We started in 2024 when I joined. On my next slide, please. A multi-year turnaround of the company. It actually started as I joined, but there were some activities already ongoing in 2023. This multi-year turnaround is based on three phases. First phase is stabilization, where we needed to stabilize the company, really focus on creating a lean, efficient, customer-focused organization. We took out operating expense out of the business, order of magnitude about $250 million of operating expenses taken out of the business. We settled legacy litigation. We streamlined our manufacturing facilities. We divested some unprofitable assets and products. That helped us to move our EBITDA from negative in 2023 to approximately $183 million positive EBITDA in 2024. A very significant turnaround in the business, and that was something we are continuing today. Our turnaround phase, where we are today, is all about where can we invest for the future of our company. We're investing right now for growth in some key products. We've got a product, TEMBEXA, which is a therapeutic for smallpox. We've got a product, raxibacumab, which is a therapeutic for anthrax. We have Ebanga, which is a product for Ebola. Obviously, Ebola is top of mind today as we think about what's happening in the news with Ebola outbreaks in Africa. Beyond that, we are also investing for international growth because we think that's another important opportunity to take our portfolio today and to diversify that by selling it to other countries around the world. That's what we do today. First quarter 2026, we reported, that was a very strong quarter for us. It was ahead of our expectations, both on revenue and EBITDA. It was slightly down from a year ago in that there was a one-time order received in the first quarter of 2025 that did not repeat. On balance, if I go to next slide, please. The next slide, please. On balance, though, it was ahead of our expectations both on revenue and EBITDA. Revenue was $156 million, EBITDA, $36 million. Importantly, we improved our cash balance. We're generating significant cash to $160 million, up $11 million versus last year. We also are continuing to work to improve our capital allocation. We refinanced our term loan to 2031, so extending the maturity of our term loan, while we also continued our share repurchase program. Indeed, on the business side, we were successful in gaining four contracts, that extended our growth during the first quarter of 2026. NARCAN, we also introduced some new innovation. We introduced a carrying case. Carrying case is perfect for those young adults that carry a backpack. It's something they can clip onto their backpack, which unfortunately, if one of their friends overdoses on an opioid, they have the ability to help that person right away. Every second counts when you have an opioid overdose, because once the person overdoses, they stop breathing, and once they stop breathing, you need to do something quickly or else the person will die. That's an important part of the carrying case. We also realized many of our customers are using large quantities as first responders. We came out with a multiple pack, six count, 24 count. We think that's going to help our most important customers that use it every day to help people to also have a large quantity, make it more efficient. We also did some new business development in the first quarter. We licensed in a product from Substipharm. We'll make the active ingredient for them. They can sell that product around the world, and that's what they needed, somebody that can make active ingredient. We have that capability. It's a live attenuated virus. We have that drug substance capability. Beyond that, they needed some expertise, and they got that expertise from us as we're going to make the product active ingredient. We also have the ability to take that product and potentially have it available for the U.S. government. That's why we think that's an important opportunity. We also added another business development program in our Canadian facility, with SAB. If I go to my next slide, this looks at the medical countermeasures biodefense. Specifically, I mentioned we are seeking to diversify the business. We, in the first quarter of 2026, have about 37% of our business from outside the U.S. That's an important diversification historically. About 15% of our business came from outside the U.S. This time it's now up to 37%. It's an important way for us to diversify, what we're trying to do with our business going forward. In addition to that, we did receive four additional contract awards. We received $140 million contract grant from the Canadian government for a number of products in Canada. We also were able to get a big contract with the U.S. government for $54 million and a $21 million BioThrax to supply the U.S. Department of Defense. All this designed to ensure that we continue to partner with governments all around the world, to make sure that we help them prepare for an uncertain future and what is increasingly a dangerous world out there. If I go to my next slide, it's about naloxone, our NARCAN products, and what we're doing there. What's the issue with opioid overdoses? Unfortunately, while they are declining the number of overdose deaths, they still exist with significant numbers. Historically, there are approximately about 100,000 overdose deaths, most of them in the area of opioids. That number has come down. The latest numbers in 2025 with approximately 50,000 opioid overdose deaths. It's still a major problem. It's come down, to be clear, it's still a major problem. We think a big part of the success of bringing that number is what we've been doing with our NARCAN product. We made our product available by working with the U.S. government to make it an over-the-counter product, the product can be sold without a prescription. We believe that was really important to make sure we'd have it more accessible to the population, just in case there was a problem. As I said, it's just like our medicine. It's just like a fire extinguisher. You want it in every home. Hopefully, you never need it, if you do, it can save lives. That's what we're looking at for what we do with our NARCAN product, to make it available over-the-counter, make it more accessible. If we are able to do that, by making it not just in the home, as I said before, put it on a carrying case that you can clip onto a backpack. We think things like that will just make it more accessible at the time of need, which is what we think will help bring down the overall opioid overdose death. That's where we sit today. We also think the other driving force for increasing the amount of unit volume for opioid overdoses, is that not only are people dying, we're also seeing a large amount of funds that are coming in, settlements from large pharma companies that sold opioid products. They've now settled class action lawsuits. There's about $50 billion coming into the marketplace of settlement funds. Those funds are going direct to the states from the large pharma companies, we believe that will be an important part from a pharmaceutical expense area, that settlement funds will come to the states. The states will use that for education and for treatment of opioid overdoses, of which we believe NARCAN will receive a certain amount of funding there. That's going to happen over the next 10 years, ballpark $50 billion next 10 years, approximately $5 billion a year coming into the settlements there of funds that will help the states to reduce the number of opioid overdose deaths. We're excited about being able to help the states to do that. If I go to my next slide, this just looks at some other financial metrics for the first quarter. I think what you can see certainly is that, number one, it exceeded our expectations, both on revenue and EBITDA, we got strong management of our operating expense. That was about down $10 million from last year. All that designed to improve our overall performance of our company as we face the opportunities in front of us in terms of continuing to protect and save lives by bringing out our products for the opioid overdose and to help governments around the world to prepare for public health threats like the biodefense area. If you look at my next page, it looks at what we're doing specifically on some of the other financial metrics. I mentioned cash. We improved our cash versus a year ago by $11 million, improved liquidity by $11 million. Importantly, though, if you look at what we've done on debt reduction, the debt reduction is down $110 million from a gross point of view and $122 million on net debt. We think that's an important metric for us to reduce the risk of our company by bringing down the overall amount of debt. As you can see from leverage from a year ago, which was 2.7x a year ago, is now down to 2.4x. We're making good progress in reducing the debt levels of our company, generating cash, and then importantly, generating the business that we get from governments around the world. We're excited about what it means for us as a company and as we think about the future as we are turning around the company. To be clear, some quarters are going to be stronger than other quarters. We've said that on our earnings call. We think directionally, we're making good progress in first stabilizing the company and now investing for the turnaround phase of our company. If I go to the next page, it looks at our debt refinancing. I mentioned briefly before, we closed a $150 million new term loan in our company. It will bring down our interest expense by approximately 200 basis points. It will help us to preserve the liquidity in our company, and it allows us to extend the maturity of our debt stack until 2031 in terms of this term loan. All good reasons. By what I was saying previously, it gives a little bit more flexibility on some of the debt covenants as we think about the future. As we think about what are we going to do in the future of our company, how are we going to allocate capital, if I go to my next page, please. The capital allocation priorities for us are very straightforward, very clear. First and foremost, we want to fund growth. Our MCM business has an international growth opportunity. We're going to continue to fund that, as well as investing in our own internal R&D business development for the products that I mentioned previously, products like raxibacumab for anthrax, TEMBEXA for smallpox, and Ebanga for Ebola, all cases of us investing in the future of our company. Beyond that, we're looking at our debt to refinance and reduce our total quantum of debt. We've made good progress, as I mentioned to you before. We're going to continue to look to reduce our total quantum of debt. Finally, we initiated a share repurchase program last year. We're happy to announce we continue to move forward with our share repurchase program and our market cap continues where we are today. We're going to continue to repurchase shares as we think the overall value of our company is being understated by the market as we sit here today. If I move to the next page. One more, please. This is where we are focused for the future in terms of what we think are multiple growth opportunities. First and foremost, the number one for us is to look as we enter the turnaround phase, where can we invest for growth? I mentioned before, we've got three products that are important to us. TEMBEXA for the treatment of smallpox. We're now beginning to test it not for smallpox only, but also now for mpox. That has started. We have Ebanga for Ebola and then raxibacumab for anthrax. Those are all things that are happening as we sit here today. We're also investing in new innovations such as NARCAN for a carrying case and multi-packs. We're investing for international expansion, all important to us. Beyond that, we're looking at what can we do for business development. Since I joined, we've done a couple of different transactions. We did KLOXXADO. It gave us the high strength of naloxone. We invest in RocketVax. RocketVax is a next-generation technology for a live attenuated virus vaccine opportunity. That product program is being funded by NIH for the phase I portion. We've just recently invested in a Japanese encephalitis virus vaccine, where we're making the raw materials, the drug substance, but then potentially look to sell it to the U.S. government in the future. More to say here on this next page. This is just a look at our pipeline, where products are. I talked about the Ebanga, TEMBEXA, and raxibacumab. We also have other candidates in different stages. We're also looking at the opportunity for pandemic flu, all opportunities that we think are going to be important at some point in the future. A lot more we're working here to look to additional products that we can add to this portfolio in 2026 and beyond. Final slide. If I look at my just closing comments here, where do I summarize? We're going to continue to invest and deliver on a multi-year transformation plan of our company. As I mentioned, we've already moved successfully through stabilization. By stabilization, we reduced our operating expense of the company. We also settled some of the legacy litigation that was a part of our company. We've improved the operating performance of our company. We've increased our cash flow generation. We think all important metrics for what we were thinking about for the future. Beyond that, we're going to continue to operate a lean, efficient, customer-focused organization. We're going to work to decrease debt, to decrease our interest expense. We'll look to repurchase our shares based on where we are today. We're looking to continue to grow and diversify our business, importantly, investing for that growth today, thinking about the future tomorrow. Those are all the things that we're looking to do while we have an ongoing commitment to how we are focusing on patient safety, quality, and making sure everything we do is in a very compliant manner. Thank you very much for the opportunity to talk today about Emergent BioSolutions and our opportunities for the future. Thank you. Have a good day, everyone.